

Apicomplexa z.B. Coccidia; Toxoplasma, Cryptospora, Isospora, Plasmodia, Babesia, Protomyxzoa rheumatic, "Sporentierchen, Sporozoen"

Robert Koch Institut (2015) **Toxoplasmose**. RKI-Ratgeber für Ärzte

http://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Toxoplasmose.html;jsessionid=502BAFD35AAF5E80E83F609CEC8D7C33.2_cid381#doc2390224bodyText9

<http://www.kabilahsystems.de/antibioseetherapieplan.pdf>

<http://www.xerlebnishaft.de/antibioseetherapie.pdf>

Tyzzar EE, (1907) A **sporozoan** found in the peptic glands of the common mouse. Proc. Soc. Exp. Biol. Med. 5, 12–13

Tyzzar EE (1912) *Cryptosporidium parvum* (sp. nov.), a coccidium found in the small intestine of the common mouse. Arch. Protistenkd. 26, 394–412

Levine ND (1970) Taxonomy of the Sporozoa. Journal of Parasitology 56 (sec. II) 208-209.

Levine ND (1971) Uniform Terminology for the Protozoan Subphylum Apicomplexa. Journal of Eukaryotic Microbiology 18 (2), 352-355.

Levine ND (1985) Phylum II. Apicomplexa. In: Lee, J.J., Hutner, S.H., and Bovee, E.C. (eds.) An Illustrated Guide to the Protozoa. Society of Protozoologists, Lawrence, Kansas.

Stibbs HH. (1985) Changes in brain concentrations of catecholamines and indoleamines in *Toxoplasma gondii* infected mice. Ann Trop Med Parasitol. 79, 153–157. [[PubMed](#)]

Korich DG, Mead JR, Madore MS et al. (1990) Effects of ozone, chlorine dioxide, chlorine, and monochlorine on *Cryptosporidium parvum* oocyst viability. Appl Environ Microbiol, 56 (5), 1423-8.

Hassl A (1991) Eine asymptomatische Kryptosporidien (Apicomplexa: Coccidia)-Infektion bei *Agalychnis callidryas* (Cope, 1862) (Anura: Hylidae). Herpetozoa 4(3/4), 127-131
http://www.landesmuseum.at/pdf_frei_remote/HER_4_3_4_0127-0131.pdf

Heyworth MF (1992) Immunology of *Giardia* and *Cryptosporidium* infections. J Infect Dis, 166 (3), 465-72.

Doyle PS, Crabb J, Petersen C (1993) Anti-*Cryptosporidium parvum* antibodies inhibit infectivity in vitro and in vivo. Infect Immun, 61 (10), 4079-84.

Flanigan TP, Soave R (1993) *Cryptosporidiosis*. Prog Clin Parasitol, 1-20

Casemore DP, Garder CA, O'Mahony C (1994) *Cryptosporidial* infection, with special reference to nosocomial transmission of *Cryptosporidium parvum*: a review. Folia Parasitol, 41 (1), 17-21

Flegr J, Hrdy I. (1994) Influence of chronic toxoplasmosis on some human personality factors. Folia Parasitol. 41, 122–126. [[PubMed](#)]

Jakubowski W (1995) *Giardia* and *Cryptosporidium*: The Details. Safe Drinking Water Act Seminar, U.S. Environmental Protection Agency.

- Johnson DW, Pieniazek NJ, et al. (1995) Development of a PCR protocol for sensitive detection of *Cryptosporidium* oocysts in water samples. *Appl Environ Microbiol*, 61 (11), 3849-55.
- Juranek DD (1995) Cryptosporidiosis: sources of infection and guidelines for prevention. *Clin Infect Dis*, 21 Suppl 1, 57-61.
- Keusch GT, Hamer D, Joe A et al. (1995) Cryptosporidia--who is at risk? *Schweiz Med Wochenschr*. 125 (18), 899-908.
- Wagner-Wiening C, Kimmig P (1995) Detection of viable *Cryptosporidium parvum* oocysts by PCR. *Appl Environ Microbiol*, 61 (12), 4514-6.
- Escalante AA, Ayala FJ (1995) Evolutionary origin of Plasmodium and other Apicomplexa based on ribosomal-RNA genes. *Proc Natl Acad Sci USA* 92, 5793—5797
- Goodgame RW (1996) Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora. *Ann Intern Med*, 124 (4), 429-41
- Clark DP, Sears CL (1996) The pathogenesis of cryptosporidiosis. [Parasitology Today 12:221](#)
- Flegr J, Zitkova S, Kodym P, Frynta D. (1996) Induction of changes in human behaviour by the parasitic protozoan *Toxoplasma gondii*. *Parasitology*. 113, 49–54. [[PubMed](#)]
- Guerrant RL (1997) Cryptosporidiosis: an emerging, highly infectious threat. [Emerg. Inf. Dis. 3:51](#)
- Flegr J, Hrda S, Tachezy J. (1998) The role of psychological factors in questionnaire-based studies on routes of human toxoplasmosis transmission. *Cent Eur J Public Health*. 6, 45–50. [[PubMed](#)]
- Flegr J, Havlicek J. (1999) Changes in the personality profile of young women with latent toxoplasmosis. *Folia Parasitol (Praha)* 46, 22–28. [[PubMed](#)]
- Flegr J, Kodym P, Tolarova V. (2000) Correlation of duration of latent *Toxoplasma gondii* infection with personality changes in women. *Biol Psychol*. 53, 57–68. [[PubMed](#)]
- Perkins, F. O., J. R. Barta, R. E. Clopton, M. A. Peirce, and S. J. Upton. (2000) Phylum **Apicomplexa**. In: Lee, J. J., G. F. Leedale, und P. Bradbury, eds. *An Illustrated Guide to the Protozoa*. 2nd ed. Society of Protozoologists. Lawrence, KS. Vol 1. pp.190-369.
- Herwaldt BL (2000) **Cyclospora cayetanensis**: A review focusing on the outbreaks of cyclosporiasis in the 1990s. [Clin. Inf. Dis. 31:1040](#).
- Tenter AS, Heckenroth AR, Weiss LM (2000) **Toxoplasma gondii**: from animals to humans. [Int. J. Parasitol. 30, 1217-1258](#)
- Havlicek J, Gasova Z, Smith AP, Zvara K, Flegr J. (2001) Decrease of psychomotor performance in subjects with latent 'asymptomatic' toxoplasmosis. *Parasitology*. 122, 515–520. [[PubMed](#)]
- Roberts CW, Walker W, Alexander J. (2001) Sex-associated hormones and immunity to protozoan parasites. *Clin Microbiol Rev*. 14, 476–488. [[PMC free article](#)] [[PubMed](#)]
- Schuster JP, Schaub GA. (2001) Experimental Chagas disease: the influence of sex and psychoneuroimmunological factors. *Parasitol Res*. 87, 994–1000. [[PubMed](#)]

Flegr J, Havlicek J, Kodym P, Maly M, Smahel Z. (2002) Increased risk of traffic accidents in subjects with latent toxoplasmosis: a retrospective case-control study. *BMC Infect Dis.* 2, 11. [[PMC free article](#)] [[PubMed](#)]

Rose JB, Huffman DE, Gennaccaro A (2002) Risk and control of waterborne **cryptosporidiosis**. *FEMS Microbiol. Rev.* 26, 13

Morrisette NS, Sibley LD (2002) Cytoskeleton of Apicomplexan Parasites. *Microbiology and Molecular Biology Reviews.* 66(1), 21-38 <http://mmlbr.asm.org/content/66/1/21.short>

Kuvardina ON, Leander BS, Aleshin VV et al. (2002) The phylogeny of colpodellids (Alveolata) using small subunit rRNA gene sequences suggest they are the free-living sister group to Apicomplexans. *Journal of Eukaryotic Microbiology* 49: 498-504.

Wilson RJM (2002) Progress with parasite plastids. *Journal of Molecular Biology* 319: 257-274.

Hill D, Dubey JP (2002) **Toxoplasma gondii**: transmission, diagnosis and prevention. *Clinical Microbiology and Infection* 8:634-640.

Flegr J, Preiss M, Klose J, Havlicek J, Vitakova M, Kodym P. (2003) Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite *Toxoplasma gondii* Dopamine, a missing link between schizophrenia and toxoplasmosis? *Biol Psychol.* 63, 253–268. [[PubMed](#)]

JM Shields and BH Olson (2003) *Cyclospora cayentanensis*: a review of an emerging parasitic coccidian. *International Journal for Parasitology* 33, 371-391.

Holland GN (2003) Ocular **toxoplasmosis**: a global reassessment: part I: epidemiology and course of disease. *American Journal of Ophthalmology* 136, 973-988.

Holland GN (2004) Ocular **toxoplasmosis**: a global reassessment: part II: disease manifestations and management. *American Journal of Ophthalmology* 137, 1-17.

Mansfield LS, Gajadhar AA (2004) *Cyclospora cayentanensis*, a food- and waterborne coccidian parasite. *Veterinary Parasitology* 126, 73-90.

Xiao L and Ryan UM (2004) Cryptosporidiosis: an update in molecular epidemiology. *Current Opinions in Infectious Disease* 17, 483-490.

Duszynski DW, Steve J et al. (2004-02-21). "[The Coccidia of the World](#)" (Online database). Department of Biology, University of New Mexico, and Division of Biology, Kansas State University

Montoya JG, Liesenfeld O (2004) **Toxoplasmosis**. *The Lancet* 363, 965-1976.

Ramirez NE, Ward LA, Sreevatsan S (2004) A review of the biology and epidemiology of cryptosporidiosis in humans and animals. *Microbes and Infection* 6, 773-785.

Sunnotel, O et al (2006) Cryptosporidium. *Letters in Applied Microbiology* 43, 7-16.

DE Hill, S Chirukandotha and JP Dubey (2005) Biology and epidemiology of **Toxoplasma gondii** in man and animals. *Animal Health Research Reviews* 6. 41-61.

Novotna M, Hanusova J, Klose J, et al. (2005) Probable neuroimmunological link between *Toxoplasma* and cytomegalovirus infections and personality changes in the human host. *BMC Infect Dis.* 5. [[PMC free article](#)] [[PubMed](#)]

Flegr J, Hruskova M, Hodny Z, Novotna M, Hanusova J. (2005) Body height, body mass index, waist-hip ratio, fluctuating asymmetry and second to fourth digit ratio in subjects with latent toxoplasmosis. *Parasitology*. 130, 621–628. [[PubMed](#)]

Flegr J, Hrda S, Kodym P. (2005) Influence of latent 'asymptomatic' toxoplasmosis on body weight of pregnant women. *Folia Parasitol*. 52, 199–204. [[PubMed](#)]

Lindová J, Novotna M, Havlicek J, et al. (2006) Gender differences in behavioural changes induced by latent toxoplasmosis. *Int J Parasitol*. 36, 1485–1492. [[PubMed](#)]

Yereli K, Balcioglu IC, Ozbilgin A. (2006) Is *Toxoplasma gondii* a potential risk for traffic accidents in Turkey? *Forensic Sci Int*. 163, 34–37. [[PubMed](#)]

Lafferty KD. (2006) Can the common brain parasite, *Toxoplasma gondii*, influence human culture? *Proc R Soc B Biol Sci*. 273, 2749–2755. [[PMC free article](#)] [[PubMed](#)]

Kanková Š, Šulc J, Nouzová K, Fajfrlík K, Frynta D, Flegr J. (2007) Women infected with parasite *Toxoplasma* have more sons. *Naturwissenschaften*, doi: 10.1007/s00114-006-0166-2 [[PubMed](#)]

Xiao, L. and Feng, Y. (2008) Zoonotic cryptosporidiosis. [FEMS Immunology & Medical Microbiology 52, 309-323](#)

Gargala G (2008) **Drug treatment and novel drug target against *Cryptosporidium***. *Parasite* 15 (3), 275–81. doi:10.1051/parasite/2008153275. PMID 18814694

Jirku M, Valigurová A, Koudela B (2008) New species of *Cryptosporidium* Tyzzer, 1907 (Apicomplexa) from Amphibian host: morphology, biology and phylogeny *FOLIA PARASITOLOGICA* 55, 81–94 <http://www.paru.cas.cz/docs/documents/40-55-2-Jirku-81.pdf>

Moore RB, Obornik M, Janouskovec J et al. (2008). A photosynthetic alveolate closely related to apicomplexan parasites. [Nature 451, 959-96](#)

Ortega YR, Sanchez R (2010) *Cyclospora cayetanensis*, a food-borne and waterborne parasite. [Clin. Microbiol. Rev. 23, 218-234](#).

de Souza W (2010) *Structures and Organelles in Pathogenic Protists*. Springer, Berlin 1., st Edition.

Braman M (2011) **Protozoal Infection** -- The Next Big Discovery? A New Protozoa Appears Linked To Mystery Diseases. http://www.iadvocatehealth.org/protozoal_infection0.aspx

Wieser MF (2012) <http://www.tulane.edu/~wiser/protozoology/notes/api.html>

Corson A (2012) **Protomyxzoa rheumatica**. http://protomyxzoa.org/wp-content/uploads/2013/05/Protomyxzoa_rheumatica.pdf

Schaller J (2013) FL1953 Protomyxzoa Rheumatica: An Introduction. A New Protozoa looks like Babesia or immature Malaria but is a fully new Protozoan by DNA, Behavior and CDC. <http://www.personalconsult.com/posts/FL1953.html>

[Flegr J.](#) (2013) How and why **Toxoplasma** makes us crazy. *Trends Parasitol*. pii: S1471-4922 (13)00020-2. doi: 10.1016/j.pt.2013.01.007. <http://www.ncbi.nlm.nih.gov/pubmed/23433494>

Kishore SP, Stiller JW, Deitsch KW (2013) **Horizontal gene transfer** of epigenetic machinery and evolution of parasitism in the **malaria parasite** *Plasmodium falciparum* and other apicomplexans. *BMC Evol Biol* 13(1):37

[Mendes TAO](#), [Lobo FP](#), [Rodrigues TS](#) (2013) Repeat-enriched proteins are related to host cell invasion and immune evasion in **parasitic protozoa**. *Mol Biol Evol* doi: 10.1093/molbev/mst001 <http://mbe.oxfordjournals.org/content/early/2013/01/08/molbev.mst001>

[Gajewski PD](#), [Falkenstein M](#), [Hengstler JG](#) et al. (2013) **Toxoplasma gondii impairs memory in infected seniors**. *Brain Behav Immun*. pii: S0889-1591(13)00578-3. doi: 10.1016/j.bbi.2013.11.019. <http://www.ncbi.nlm.nih.gov/pubmed/24321215?dopt=Abstract#>
“Almost 30% of humans present a *Toxoplasma gondii* positive antibody status and its prevalence increases with age. The central nervous system is the main target ...”.

Muniz-Feliciano L, Van Grol J, Portillo J-AC et al. (2013) *Toxoplasma gondii*-Induced Activation of EGFR Prevents Autophagy Protein-Mediated Killing of the Parasite. *Research Article*. *PLOS Pathogens*. DOI: 10.1371/journal.ppat.100380
<http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1003809>
EGFR = Epidermal Growth Factor Receptor <http://de.wikipedia.org/wiki/EGF-Rezeptor>

McConkey GA, Martin HL, Bristow GC, Webster JP (2013) **Toxoplasmosis gondii infection and behaviour-location, location, location?** *J Exp Biol* 216, 113-9

Hannahs G, **Cryptosporidium parvum**: an emerging pathogen.
<http://biology.kenyon.edu/slouc/bio38/hannahs/crypto.htm>

[Carter CJ](#). (2013) **Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders**. *J Pathog*. 2013, 965046. doi: 10.1155/2013/965046.
<http://www.ncbi.nlm.nih.gov/pubmed/23533776>

[Fond G](#), [Boyer L](#), [Gaman A](#) (2015) **Treatment with Anti-Toxoplasmic Activity (TATA) for Toxoplasma positive patients with bipolar disorders or schizophrenia: a cross-sectional study**. *Journal of psychiatric research*. DOI: <http://dx.doi.org/10.1016/j.jpsychires.2015.02.011>
„It seems to be of importance to consider prescribing a drug with a clear anti-toxoplasmic activity (TATA+) for BD patients seropositive to *T. gondii*, in particular valproate that was found as the mood stabilizer with the highest antitoxoplasmic activity“.

Sparks H, Nair G, Castellanos-Gonzalez A, White AC (2015) **Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward**. *Curr Trop Med Rep* 2 (3), 181–187. doi:10.1007/s40475-015-0056-9. PMID 26568906
<https://www.ncbi.nlm.nih.gov/pubmed/26568906>
« Currently, nitazoxanide is the only proven anti-parasitic treatment for *Cryptosporidium* infections. However, it is not effective in severely immunocompromised patients and there is limited data in infants.”

Sutterland AL, Fond G, Kuin A et al. (2015) **Beyond the association. Toxoplasma gondii in shizophrenia, bipolar disorder and addiction: systematic review and meta-anaysis**. *Acta Psychiatr Scand* 132, 161-79

The Stanley Medical Research Institute (2017) **Toxoplasmosis–Schizophrenia Research**
<http://www.stanleyresearch.org/patient-and-provider-resources/toxoplasmosis-schizophrenia-research/>

[Daryani A](#), [Montazeri M](#), [Pagheh AS](#) et al. (2017) **The potential use of melatonin to treat protozoan parasitic infections: A review**. *Biomed Pharmacother*. 97, 948-957. doi: 10.1016/j.biopha.2017.11.007. [Epub ahead of print]
« Due to the antioxidant and immunomodulatory effects of melatonin, it is suggested that this molecule could be a therapeutic alternative agent to fight bacterial, viral, and parasitic infections by a variety of

mechanisms. Herein, we review the effects of melatonin on the cell biology of protozoan parasites and host's immune response. «

[Flegr J1, Horáček J](#) (2018) **Toxoplasmosis, but not borreliosis, is associated with psychiatric disorders and symptoms.** [Schizophr Res.](#) pii: S0920-9964(18)30057-4. doi: 10.1016/j.schres.2018.02.008. [Epub ahead of print]

Pleyer U, Groß U, Schlüter D et al. (2019) **Toxoplasmose in Deutschland.** Deutsches Ärzteblatt 116(25), 435-443 <https://www.aerzteblatt.de/archiv/208347/Toxoplasmose-in-Deutschland>
Pleyer U, Gross U, Schlüter D et al (2019) **Toxoplasmosis in Germany-epidemiology, diagnosis, risk factors, and treatment.** Dtsch Arztebl Int 116, 435-44
„**Erstinfektion in der Schwangerschaft, bis 16 SSW: Spiramycin (3,0 g = 9 MiU/Tag)**
Koninatale Toxoplasmose des Neugeborenen, in Abhängigkeit vom Schweregrad für 3-12 Monate:
Pyrimethamin (1 mg/kg KG/Tag) plus Sulfadiazin (50-100 mg/KG KG/Tag) plus Folsäure (2-3 mg/Woche)
Retinochorioiditis, Pyrimethamin (50 mg/1.Tag, 25 mg ab 2.Tag) plus Sulfadiazin (50 mg/kg KG/Tag plus Folsäure (10-15 mg/Tag) oder Clindamycin (1,2-2,4 g/Tag) oder Trimethoprim/Sulfamethoxazol (Cotrimazol) (960 mg/Tag) oder Atovaquon (3x750 mg/Tag)
Zerebrale Toxoplasmose, Pyrimethamin (50 mg/1.Tag, 25 mg ab 2.Tag) plus Sulfadiazin (50 mg/kg KG/Tag plus Folsäure (10-15 mg/Tag) Alternativ: ggf. Cotrimoxazol (960 mg/Tag) oder Atovaquon (3x750 mg/Tag)“

Burgdorf KS, Trabjerg BB, Pedersen MG et al. (2029) **Large scale study of toxoplasma and cytomegalovirus shows an association between infection and serious psychiatric disorders.** Brain Behav Immun 79, 152-8

- ➔ Babesien <http://www.kabilahsystems.de/babesien.pdf>
- ➔ Mikrofilarien <http://www.xerlebnishaft.de/mikrofilarien.pdf>
- ➔ Therapie Fungi <http://www.kabilahsystems.de/fluconazol.pdf>
- ➔ Virusarten, viruses <http://www.kabilahsystems.de/immunsti.pdf>
- ➔ Das Zytoskelett und die Neurotoxine <http://www.kabilahsystems.de/ph.pdf>
- ➔ Das Zytoskelett www.xerlebnishaft.de/zytoskelett.pdf

- ➔ Krebsstammzelltherapie (Salinomycin) <http://www.xerlebnishaft.de/krebsstammzelltherapie.pdf>

[Bernt - Dieter Huismans](#). Letzte Revision Oktober 2019 www.Huismans.click 
Back to top: <http://www.kabilahsystems.de/toxoplasmen.pdf>